psoriatic arthritis (psa) treatment methods using il-17 antagonists and psa response or non-response alleles

摘要

patent summary: "methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non-response alleles". The present invention relates to novel predictive methods and personalized therapies for the treatment of psoriatic arthritis (psa). Specifically, the present invention relates to methods of treating a psa patient by selectively administering an il-17 antagonist, for example an il-17 antibody, such as secukinumab, to the psa-based patient. that the patient is predisposed to have a favorable response to il-17 antagonist treatment. Also useful in the present invention are diagnostic methods useful for predicting the likelihood that a patient with psa will respond to treatment with an IL-17 antagonist. il-17, for example, an il-17 antibody, such as secukinumab.